家庭氧疗对慢阻肺中度低氧血症患者生存影响的系统综述与荟萃分析
该系统综述与荟萃分析检索多个数据库至2022年1月13日,纳入6项平行组随机试验,其中5项(1002例)进入主要荟萃分析。
要点
- 家庭氧疗对慢阻肺中度低氧血症患者3年死亡率影响小或无差异。
- 证据不支持在该患者群体中广泛使用家庭氧疗。
核心结论
- 家庭氧疗对慢阻肺合并中度低氧血症患者的3年死亡率可能几乎无影响。
- 现有数据不支持在该患者群体中广泛使用家庭氧疗。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、Cochrane CENTRAL、CINHAL和Web of Science至2022年1月13日。
- 纳入长期或夜间氧疗的平行组随机试验,对照为常规护理或通过假浓缩器给予环境空气(安慰剂)。
- 排除交叉试验和严重低氧血症试验,主要结局为3年死亡率。
- 共识别2192项研究,去重后筛选1447项,全文筛选161项,最终纳入6项随机试验(1992-2020年发表),证据质量高。
- 主要荟萃分析纳入5项试验共1002例患者,采用随机效应模型。
主要发现
- 95%CI下限未达到预设的最小临床重要差异(3年随访死亡率相对风险降低30-40%)。
关键数值与推荐
- 预设最小临床重要差异为3年随访死亡率相对风险降低30-40%。
临床怎么用
- 对于慢阻肺合并中度低氧血症(不符合长期氧疗标准,包括孤立性夜间血氧饱和度下降)患者,不应常规广泛处方家庭氧疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term oxygen therapy (LTOT) improves survival in patients with chronic obstructive pulmonary disease (COPD) and severe hypoxaemia. However, the best method of management of moderate hypoxaemia not qualifying for LTOT (including isolated nocturnal desaturation) is uncertain. We examined the effect of home oxygen (either LTOT or nocturnal oxygen therapy) on overall survival in patients with COPD and moderate hypoxaemia. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, CINHAL, and Web of Science from database inception to Jan 13, 2022, for parallel-group randomised trials of long-term or nocturnal oxygen in patients with COPD and moderate daytime hypoxaemia or isolated nocturnal desaturation, or both. Control groups received usual care or ambient air through sham concentrators (placebo) throughout the study period. The primary outcome of interest was 3-year mortality. Crossover trials and trials of oxygen in severe hypoxaemia were excluded. Two reviewers applied inclusion and exclusion criteria to titles and abstracts and screened the full-text articles and reference lists of relevant studies. Aggregate data were extracted manually in duplicate using structured data collection forms. Methodological quality was assessed using the Cochrane Risk of Bias tool. Random-effects meta-analysis was used to pool individual studies. We considered the minimal clinically important difference for home oxygen to be a relative risk reduction in mortality at 3-year follow-up of 30-40%. The meta-analysis is registered on PROSPERO, CRD42021225372. FINDINGS: We identified 2192 studies and screened 1447 after removal of duplicates, of which 161 were subjected to full-text screening, and six were identified as being eligible for inclusion. These six randomised trials were published between 1992 and 2020 and the quality of evidence was high. In the primary meta-analysis (five trials; 1002 patients), we found the effect of home oxygen in reducing 3-year mortality to be small or absent (relative risk 0·91 [95% CI 0·72-1·16]; τ2 = 0·00), hence the lower limit of the 95% CI did not meet the prespecified minimal clinically important difference. INTERPRETATION: The results of our meta-analysis suggest that home oxygen probably makes little or no difference to 3-year mortality in patients with COPD and moderate hypoxaemia. The data do not support the widespread use of home oxygen in this patient population. FUNDING: None.
引用
- Lacasse Y, Casaburi R, Sliwinski P, et al. Home oxygen for moderate hypoxaemia in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2022. PMID: 35817074. doi:10.1016/S2213-2600(22)00179-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。